Rheumatology Live

03/25/2026

Jack Arnold, MBBS, PhD University of Leeds discusses the growing use of GLP-1 RAs in rheumatology with Rihards Buss, MD, in our latest Joint Ventures episode. Watch the conversation now:

https://hubs.li/Q048njK30

03/24/2026

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE at . Learn more:

Ronald F. van Vollenhoven, MD, PhD, discusses 5-year real-world follow-up that show belimumab stays broadly safe in SLE.

03/19/2026

A decision on SunPharma's tildrakizumab for psoriatic arthritis is expected by the end of October 2026, as per its recent FDA sBLA acceptance. Read more:

The FDA has set a PDUFA of October 29, 2026, for the therapy's application.

03/19/2026

Roy Fleischmann, MD, University of Texas Southwestern Medical Center. discussed new modalities emerging in the rheumatology field, with the closest frontier in . Watch now:

https://hubs.li/Q047sXP_0

03/17/2026

February's updates included impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast. Learn more:

This rheumatology month in review emphasizes impactful conversations from RWCS 2026 and the launch of the Joint Ventures podcast.

03/13/2026

Take a look back at 5 impactful conversations ranging from PsA to giant cell arteritis from in Maui, Hawaii now:

https://hubs.li/Q046F-N00

03/11/2026

Anisha Dua, MD, MPH, Northwestern Medicine, discussed how new advances like sarilumab and promising biologic secukinumab are transforming PMR management. Watch now:

https://hubs.li/Q046jqSr0

03/10/2026

Orrin Troum, MD, and Alvin Wells, MD, PhD, discussed advances in 2025 that are continuing to transform the systemic autoimmune diseases at . Watch now:

Wells and Troum discussed advances in 2025 that are continuing to transform the systemic autoimmune diseases.

03/06/2026

Dr. Naomi Patel from Brigham and Women's Hospital/Mass General Brigham discussed findings from retrospective cohort study of avacopan in MPA/GPA at . Watch now:

Patel shared findings from a retrospective cohort study in people with GPA or MPA at RWCS 2026.

03/04/2026

Nipocalimab receives Fast Track designation for systemic erythematosus, supported by data from the phase 2b JASMINE study. Read more:

The decision is supported by data from the phase 2b JASMINE study which will be presented at a future medical meeting.

03/02/2026

A little look back at our Spelling Bee 🐝

Test your knowledge alongside the experts — how many would you get right?

Thank you to Alvin Wells, MD, PhD and Orrin Troum, MD for joining in on the fun 👏

02/26/2026

Watch our conversation with Susan Shenoi, MD, MS at on addressing pediatric rheumatology workforce shortages now:

https://hubs.li/Q044LGKk0